Last updated on December 2018

Evaluating Immune Therapy Durvalumab (MEDI4736) With Tremelimumab for Metastatic Non-transitional Cell Carcinoma of the Urinary Tract


Brief description of study

This study is being done test to test the safety and effectiveness of durvalumab combined with tremelimumab in patients who have a rare form of cancer of the urinary tract.

Clinical Study Identifier: NCT03430895

Find a site near you

Start Over